Cardio-oncology & otherRandomised controlled trial
Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial
- Randomised controlled trial
- prospective
- multicentre
- 14 sites
Authors' conclusion
In patients with isolated GLS reduction after anthracyclines, cardioprotection is associated with better preservation of 12-month MRI-LVEF compared with usual care.
Study context
- Population
- Patients receiving anthracyclines with normal baseline left ventricular ejection fraction (LVEF), ≥1 other cancer therapy-related cardiac dysfunction (CTRCD) risk factor, developing GLS-CTRCD (>12% relative global longitudinal strain (GLS) reduction without LVEF change)randomised of 333 tracked
- Participants
- 105 patients
- Comparison
- Cardioprotection with neurohormonal antagonists vs usual care
- Cardioprotectionn = 49
- Usual caren = 56reference
- Primary endpoint
- Change in MRI-LVEF
- Follow-up
- 12 months
Primary result
12-month change in MRI-LVEF
Mean difference
−3.6 %
95% CI −1.8% to −5.5%
P < 0.001
By group
Cardioprotection
−2.5
mean change · SD 5.4 · %
Usual care
−5.6
mean change · SD 5.9 · %
As reported in the abstract
Secondary outcomes
Follow-up LVEF · 12 months
P < 0.0001
| Outcome | Cardioprotection | Usual care | P value |
|---|---|---|---|
| MRI-LVEF-defined CTRCD · 12 months | 1/49 | 6/56 | P = 0.075 |
GLS · 3 months post-randomisation
- GLS improved with cardioprotection, little change with usual care
Deaths and HF during follow-up
- Deaths
- 2
- HF
- 2
Safety
- Side-effects attributed to cardioprotection
- 43% · 21 of 49
Original publication
Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial. Eur Heart J. Published 1 September 2024. doi:10.1093/eurheartj/ehae574
Summarised from the published abstract; every number is checked against it